Review finds cannabidiol ineffective amid mixed dyspepsia treatment evidence

This systematic review asked which treatments help adults with functional dyspepsia, a gut-brain interaction disorder. It examined randomized clinical trials from the past ten years involving adults who met Rome III or IV criteria. The abstract reports no sample size or quantitative effect estimates. Its main finding is that prokinetics showed no consistent benefit, and cannabidiol was reported as ineffective.

Results varied by symptom pattern: low-FODMAP eating was not better than conventional dietary advice overall, though a subgroup with abdominal distension showed a signal of benefit; mirtazapine showed signals of benefit for weight loss or early satiety; and low-dose amitriptyline was superior to pantoprazole for epigastric pain syndrome. Several other approaches also showed possible benefits, but these signals mostly came from single trials. The review favors a personalized, stepwise, biopsychosocial approach. This is an abstract-based summary: without the full text or quantitative results, it cannot establish the size or certainty of treatment effects, and the abstract does not provide enough detail to assess the cannabidiol finding further.